Clinical Trials Logo

Filter by:
NCT ID: NCT05887700 Not yet recruiting - Clinical trials for Atrial Septal Defect

Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up

Start date: May 2024
Phase:
Study type: Observational

The objective of this post-market registry is to assess the clinical use of the Lifetech CeraFlex™ Closure System in a real-world and on-label fashion.

NCT ID: NCT05886088 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

DÁLIA
Start date: February 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.

NCT ID: NCT05884034 Not yet recruiting - Quality of Life Clinical Trials

Effects of a Self-care Educational Program Via Telerehabilitation in Caregivers

Start date: June 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of a self-care educational program via telerehabilitation on the quality of life, burden, stress, pain, and depression of caregivers of people with ALS.

NCT ID: NCT05876546 Not yet recruiting - Skin Care Clinical Trials

Evaluation of Skin Irritancy and Sensitization of a Liquid Bandage

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The investigational product constitutes a medical device that is freely accessible to consumers and, as such, must be safe under real or reasonably foreseeable conditions of use and its safety must be tested before being placed on the market. Therefore, this study was designed to evaluate the biocompatibility of the experimental product, as provided for in legislation.

NCT ID: NCT05871983 Not yet recruiting - Clinical trials for Mitral Regurgitation

Munich Transcatheter Mitral Valve Safety and Effectiveness

MUSE
Start date: July 30, 2023
Phase: N/A
Study type: Interventional

The Munich Trascatheter Mitral Valve System is intended for beating heart, mitral valve replacement in patients with a diseased, damaged, or malfunctioning mitral valve. Access is provided through the Femoral Vein and transseptal approach by means of a 27Fr catheter. The bioprosthetic valve consists of a self-expanding, tri-leaflet, dry bovine-pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The valve is available in three sizes and has been designed to reduce the complexity of implantation in comparison to other TMVR systems.

NCT ID: NCT05852626 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 2

Structuring of Diabetes Care in Primary Health Care

Start date: May 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effectiveness of reorganization in Primary Health Care teams and individualized glycemic targets for type 2 diabetes.

NCT ID: NCT05847075 Not yet recruiting - Type 2 Diabetes Clinical Trials

Heat Therapy and Strength Training Effects in Individuals With Type 2 Diabetes

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to compare different non-pharmacological interventions in Type 2 diabetic people, testing their efficiency to improve metabolism and inflammation. The investigators will compare the effects of Heat Therapy (HT) and Strength training (ST), for 12 weeks, to test which one is more effective to improve participants health. Heat Therapy consists in submitting a person to an environmental chamber, initially set at 55 degrees Celsius on three non-consecutive days of the week. Each session will last 60 min. ST consists in supervised exercise in a gym on three non-consecutive days of the week. Each session will last ~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks. A third group of people will stay sedentary without any other intervention for 12 weeks. Before, and after the end of the intervention blood samples will be collected to analyze metabolic parameters as well as inflammatory markers. The investigators hypothesize that ST and HT will reduce HbA1c levels, improve metabolic and inflammatory profile, dysbiosis, and the anti-inflammatory heat shock response (HSR).

NCT ID: NCT05824806 Not yet recruiting - Clinical trials for Osteoarthritis, Knee

Knee Osteoarthritis Treatment With Platelet-rich Plasma

Start date: August 2024
Phase: Phase 3
Study type: Interventional

Knee osteoarthritis (KOA) is a disease characterized by cartilage degeneration, synovium inflammation, bone remodeling, osteophyte formation, inflammations and loss of articular function. Interest on biological therapies has increased due to the recent update on KOA and its natural history. Viscosupplementation with hyaluronic acid aims to restore rheological properties of synovial fluid. Platelet rich plasma (PRP) is an autologous blood product which contains an elevated platelet concentration above the one found in blood. The goal of this study is to compare the clinical results of intra articular infiltration of hyaluronic and platelet rich plasma in the treatment of KOA, and to establish a protocol for PRP obtaining and prepare. Patients form the OA treating program will be selected and randomized into three groups (treatment with hyaluronic acid or onte of the two PRP protocols, PRP A and PRP B). Evaluation will include: subjective functional evaluation, clinical evaluation, radiological evaluation and radiological evaluation, which will be performed before treatment and 3 weeks, 3 months, 6 months and 1 year after treatment. Evaluation of PRP composition will be performed using ELISA/LUMINEX. Key words: Knee, osteoarthritis, platelet rich plasma, viscosupplementation.

NCT ID: NCT05824065 Not yet recruiting - Clinical trials for Female Pattern Baldness

Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

GENERA
Start date: January 2025
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.

NCT ID: NCT05814432 Not yet recruiting - Immunosuppression Clinical Trials

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).